Argenx Se reported Revenue surge of 89.08% year on year in the fourth quarter 2025, to $ 8,399.37 millions, this is lower than Argenx Se's recent average Revenue surge of 119.53%.
Looking into fourth quarter 2025 results within Biotechnology & Pharmaceuticals industry 21 other companies have achieved higher Revenue growth. While Argenx Se' s Revenue jump of 89.08% ranks overall at the positon no. 360 in the fourth quarter 2025.
Although Argenx Se's Annual Revenue growth year on year were below company's average 191.46% , Revenue announced in the Dec 31 2025 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 89.08% year on year, from 78.05% in Dec 31 2024. And, Argenx Se had the highest Revenue growth, in Biotechnology & Pharmaceuticals industry.
Among companies within the Healthcare sector 19 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 40, from total ranking in previous quarter at 66.
Although Argenx Se's Annual Revenue growth year on year were below company's average 191.46% , Revenue announced in the Dec 31 2025 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 89.08% year on year, from 78.05% in Dec 31 2024. And, Argenx Se had the highest Revenue growth, in Biotechnology & Pharmaceuticals industry.
Among companies within the Healthcare sector 19 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 40, from total ranking in previous quarter at 66.
About Argenx Se Revenue Growth Rates (ARGX), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
153.57%